A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Vorinostat (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 26 Sep 2008 New trial record.